vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and TEXAS CAPITAL BANCSHARES INC (TCBI). Click either name above to swap in a different company.
TEXAS CAPITAL BANCSHARES INC is the larger business by last-quarter revenue ($324.0M vs $247.1M, roughly 1.3× ANI PHARMACEUTICALS INC). TEXAS CAPITAL BANCSHARES INC runs the higher net margin — 22.8% vs 11.1%, a 11.6% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 15.5%). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 10.2%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Texas Capital Bank is a bank headquartered in Dallas, Texas. The bank has branches located in every major city in Texas. Its parent bank holding company is Texas Capital Bancshares. It also operates an online-only banking division, Bask Bank.
ANIP vs TCBI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $324.0M |
| Net Profit | $27.5M | $73.8M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | — |
| Net Margin | 11.1% | 22.8% |
| Revenue YoY | 29.6% | 15.5% |
| Net Profit YoY | 367.5% | 56.8% |
| EPS (diluted) | $1.14 | $1.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $324.0M | ||
| Q4 25 | $247.1M | $327.5M | ||
| Q3 25 | $227.8M | $340.4M | ||
| Q2 25 | $211.4M | $307.5M | ||
| Q1 25 | $197.1M | $280.5M | ||
| Q4 24 | $190.6M | $229.6M | ||
| Q3 24 | $148.3M | $125.3M | ||
| Q2 24 | $138.0M | $267.0M |
| Q1 26 | — | $73.8M | ||
| Q4 25 | $27.5M | $100.7M | ||
| Q3 25 | $26.6M | $105.2M | ||
| Q2 25 | $8.5M | $77.3M | ||
| Q1 25 | $15.7M | $47.0M | ||
| Q4 24 | $-10.3M | $71.0M | ||
| Q3 24 | $-24.2M | $-61.3M | ||
| Q2 24 | $-2.3M | $41.7M |
| Q1 26 | — | — | ||
| Q4 25 | 14.1% | 40.4% | ||
| Q3 25 | 15.9% | 40.5% | ||
| Q2 25 | 6.6% | 33.2% | ||
| Q1 25 | 13.3% | 21.6% | ||
| Q4 24 | -2.3% | 40.7% | ||
| Q3 24 | -13.8% | -63.8% | ||
| Q2 24 | 3.7% | 21.9% |
| Q1 26 | — | 22.8% | ||
| Q4 25 | 11.1% | 30.7% | ||
| Q3 25 | 11.7% | 30.9% | ||
| Q2 25 | 4.0% | 25.2% | ||
| Q1 25 | 8.0% | 16.8% | ||
| Q4 24 | -5.4% | 30.9% | ||
| Q3 24 | -16.3% | -48.9% | ||
| Q2 24 | -1.7% | 15.6% |
| Q1 26 | — | $1.56 | ||
| Q4 25 | $1.14 | $2.11 | ||
| Q3 25 | $1.13 | $2.18 | ||
| Q2 25 | $0.36 | $1.58 | ||
| Q1 25 | $0.69 | $0.92 | ||
| Q4 24 | $-0.45 | $1.43 | ||
| Q3 24 | $-1.27 | $-1.41 | ||
| Q2 24 | $-0.14 | $0.80 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | — |
| Total DebtLower is stronger | — | $878.3M |
| Stockholders' EquityBook value | $540.7M | $3.6B |
| Total Assets | $1.4B | $33.5B |
| Debt / EquityLower = less leverage | — | 0.24× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | — | ||
| Q2 25 | $217.8M | — | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | — | ||
| Q2 24 | $240.1M | — |
| Q1 26 | — | $878.3M | ||
| Q4 25 | — | $620.6M | ||
| Q3 25 | — | $620.4M | ||
| Q2 25 | — | $620.3M | ||
| Q1 25 | — | $660.5M | ||
| Q4 24 | — | $660.3M | ||
| Q3 24 | — | $660.2M | ||
| Q2 24 | — | $660.0M |
| Q1 26 | — | $3.6B | ||
| Q4 25 | $540.7M | $3.6B | ||
| Q3 25 | $505.8M | $3.6B | ||
| Q2 25 | $436.8M | $3.5B | ||
| Q1 25 | $418.6M | $3.4B | ||
| Q4 24 | $403.7M | $3.4B | ||
| Q3 24 | $405.9M | $3.4B | ||
| Q2 24 | $455.8M | $3.2B |
| Q1 26 | — | $33.5B | ||
| Q4 25 | $1.4B | $31.5B | ||
| Q3 25 | $1.4B | $32.5B | ||
| Q2 25 | $1.3B | $31.9B | ||
| Q1 25 | $1.3B | $31.4B | ||
| Q4 24 | $1.3B | $30.7B | ||
| Q3 24 | $1.3B | $31.6B | ||
| Q2 24 | $920.8M | $29.9B |
| Q1 26 | — | 0.24× | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.17× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.19× | ||
| Q4 24 | — | 0.20× | ||
| Q3 24 | — | 0.20× | ||
| Q2 24 | — | 0.21× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | — |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $360.2M | ||
| Q3 25 | $44.1M | $166.3M | ||
| Q2 25 | $75.8M | $63.0M | ||
| Q1 25 | $35.0M | $368.0K | ||
| Q4 24 | $15.9M | $480.1M | ||
| Q3 24 | $12.5M | $332.8M | ||
| Q2 24 | $17.4M | $33.3M |
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | $347.6M | ||
| Q3 25 | $38.0M | $161.3M | ||
| Q2 25 | $71.8M | $57.5M | ||
| Q1 25 | $32.5M | $-2.0M | ||
| Q4 24 | $13.5M | $415.2M | ||
| Q3 24 | $7.7M | $317.6M | ||
| Q2 24 | $13.0M | $11.1M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 106.1% | ||
| Q3 25 | 16.7% | 47.4% | ||
| Q2 25 | 34.0% | 18.7% | ||
| Q1 25 | 16.5% | -0.7% | ||
| Q4 24 | 7.1% | 180.9% | ||
| Q3 24 | 5.2% | 253.4% | ||
| Q2 24 | 9.4% | 4.1% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 3.8% | ||
| Q3 25 | 2.7% | 1.5% | ||
| Q2 25 | 1.9% | 1.8% | ||
| Q1 25 | 1.3% | 0.9% | ||
| Q4 24 | 1.3% | 28.2% | ||
| Q3 24 | 3.2% | 12.1% | ||
| Q2 24 | 3.2% | 8.3% |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 3.58× | ||
| Q3 25 | 1.66× | 1.58× | ||
| Q2 25 | 8.87× | 0.81× | ||
| Q1 25 | 2.23× | 0.01× | ||
| Q4 24 | — | 6.76× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
TCBI
Segment breakdown not available.
